Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mitochon Pharmaceuticals has completed its second year of funding with a total investment of $1.6m.
Subscribe to our email newsletter
The proceeds from the financing will be used to advance Mitochon’s lead compound MP101, a first in class mitochondrial targeted neuro-protective agent, into human studies, as well as, further develop MP201 for IND filing.
Investors included Ben Franklin Technology Partners and Private Investors.
"We are pleased to close on this financing and continue our efforts in developing neuro-protective compounds for insidious neurodegenerative diseases with few treatment options, including: Huntington’s Disease, Rett Syndrome, Multiple Sclerosis, Parkinson’s and Alzheimer’s Disease", said co-founders Robert Alonso, CEO and John Geisler, PhD., CSO.
"Mitochon had a remarkable 2015, with a series of successful proof-of-concept studies, that have now paved the path for clinical development".
MP101 is a mitochondrial targeted, once a day, oral therapy that has been shown to shield cells from damage caused by a host of degenerative processes (genetic, auto-immune and injury). In preclinical studies, MP101 has exhibited striking protective and functional benefits in disease models. These include: brain volume sparing in Huntington’s disease; axonal protection from demyelination in Multiple Sclerosis; and motor improvement in Rett Syndrome and Parkinson’s disease.
To understand the critical step of translation, Mitochon will initiate Phase I studies innormal healthy volunteers in 2016 and is expected to be in Huntington’s patients in 2017.